Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

View All Documentation

SML0147

Sigma-Aldrich

Drospirenone

≥98% (HPLC)

Synonyme(s) :

6β,7β:15β,16β -Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone, Dihydrospirorenone

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C24H30O3
Numéro CAS:
67392-87-4
Poids moléculaire :
366.49
Numéro CE :
266-679-2
Numéro MDL:
MFCD00867350
Code UNSPSC :
51111800
ID de substance PubChem :
329825195
Nomenclature NACRES :
NA.77

Niveau de qualité

100

Pureté

≥98% (HPLC)

Forme

powder

Activité optique

[α]/D -180 to -195°, c = 1 in methanol

Conditions de stockage

desiccated

Couleur

white to tan

Solubilité

DMSO: ≥15

Auteur

Bayer

Température de stockage

2-8°C

Chaîne SMILES 

C[C@]12CCC(=O)C=C1[C@@H]3C[C@@H]3[C@@H]4[C@@H]2CC[C@@]5(C)[C@H]4[C@@H]6C[C@@H]6[C@@]57CCC(=O)O7

InChI

1S/C24H30O3/c1-22-6-3-12(25)9-17(22)13-10-14(13)20-16(22)4-7-23(2)21(20)15-11-18(15)24(23)8-5-19(26)27-24/h9,13-16,18,20-21H,3-8,10-11H2,1-2H3/t13-,14+,15-,16+,18+,20-,21+,22-,23+,24+/m1/s1

Clé InChI

METQSPRSQINEEU-HXCATZOESA-N

Informations sur le gène

human ... NR3C2(4306) , PGR(5241)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Application

Drospirenone has been used as a progestogen agent in pond snail and fish.
Drospirenone was tested for genotoxicity in rat and human hepatocytes.

Actions biochimiques/physiologiques

Drospirenone is a fourth-generation progestin that has antimineralocorticoid, and antiandrogenic activity in addition to potent progestogenic activity. In two recent studies drospirenone appeared to double the risk of venous thromboembolism compared to levonorgestrel, although other studies found little added risk.

Caractéristiques et avantages

This compound is featured on the Nuclear Receptors (Steroids) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Bayer. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pictogrammes

Health hazard
GHS08

Mention d'avertissement

Danger

Mentions de danger

H360

Conseils de prudence

P201 - P308 + P313

Classification des risques

Repr. 1B

Code de la classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 1

1 of 1

Mifepristone ≥98%

Sigma-Aldrich

M8046

Mifepristone

Complex molecular changes induced by chronic progestogens exposure in roach, Rutilus rutilus
Maasz G, et al.
Ecotoxicology and Environmental Safety, 139, 9-17 (2017)
L M Lopez et al.
The Cochrane database of systematic reviews, (1)(1), CD006586-CD006586 (2008-02-07)
Premenstrual syndrome (PMS) is a common problem. Premenstrual dysphoric disorder (PMDD) is a severe form of PMS. Combined oral contraceptives (COCs), which have both progestin and estrogen, have been examined for their ability to relieve premenstrual symptoms. A COC containing
Cassiana R G Giribela et al.
Contraception, 86(1), 35-41 (2012-04-03)
Combined oral contraceptives (COCs) may lead to a rise in cardiovascular disease risk, possibly associated with changes in blood pressure and endothelial function. The objective was to evaluate the impact of COC containing 20 mcg of ethinylestradiol (EE) and 3
T Simoncini et al.
Climacteric : the journal of the International Menopause Society, 13(1), 22-33 (2009-11-27)
Hormone therapy is effective for the relief of menopausal symptoms. For women with a uterus, addition of a progestogen is required to protect the endometrium. However, synthetic progestins differ in certain pharmacological characteristics that may have implications for clinical practice.
Laureen M Lopez et al.
The Cochrane database of systematic reviews, (2)(2), CD006586-CD006586 (2009-04-17)
Premenstrual syndrome (PMS) is a common problem. Premenstrual dysphoric disorder (PMDD) is a severe form of PMS. Combined oral contraceptives (COCs), which have both progestin and estrogen, have been examined for their ability to relieve premenstrual symptoms. A COC containing
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique